Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C

Journal of Infection and Chemotherapy

Volumn 17, Issue 6, 2011, Pages 737-743

  Ikezaki, Hiroaki ^a,b   Furusyo, Norihiro ^a,b   Ihara, Takeshi ^a,b   Hayashi, Takeo ^a,b   Ogawa, Eiichi ^a,b   Toyoda, Kazuhiro ^a,b   Taniai, Hiroaki ^a,b   Kainuma, Mosaburo ^a,b   Murata, Masayuki ^a,b   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Interferon; RealTime PCR; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; COBAS AMPLICOR MONITOR TEST; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT MONITORING; PREDICTIVE VALUE; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA;

EID: 84855280088     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0249-7     Document Type: Article

References (38)

1. Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology. 1997;25:697-701. (Pubitemid 27106456)
2. JE Darnell Jr IM Kerr GR Stark 1994 Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1415 1421 8197455 10.1126/science.8197455 1:CAS:528: DyaK2cXktlalsL4%3D (Pubitemid 24217131)
3. MH Heim 2000 Intracellular signaling and antiviral effects of interferons Dig Liver Dis 32 257 263 10975779 10.1016/S1590-8658(00)80831-2 1:CAS:528:DC%2BD3cXltl2ntLg%3D (Pubitemid 30345358)
4. Frese M, Dazert E. Interferon-induced effector proteins and hepatitis C virus replication. In: Jirillo E, editor. Hepatitis C virus disease: immunobiology and clinical applications. USA: Springer; 2008. Chapter 6.
5. G Chander MS Sulkowski MW Jenckes MS Torbenson HF Herlong EB Bass, et al. 2002 Treatment of chronic hepatitis C. A systematic review Hepatology 36 S135 S144 12407587 10.1002/hep.1840360718
6. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1485 1492 9819446 10.1056/NEJM199811193392101 1:CAS:528:DyaK1cXnslGmtbs%3D (Pubitemid 28543496)
7. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo, et al. 1998 Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1426 1432 9807989 10.1016/S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D (Pubitemid 28510876)
8. N Furusyo M Katoh Y Tanabe E Kajiwara T Maruyama J Shimono, et al. 2006 Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group World J Gastroenterol 12 784 790 16521196 1:CAS:528:DC%2BD28XjtV2ltbY%3D (Pubitemid 43380765)
9. N Furusyo E Kajiwara K Takahashi H Nomura Y Tanabe A Masumoto, et al. 2008 Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients : a project of the Kyushu University Liver Disease Study Group J Gastroenterol Hepatol 23 1094 1104 18248381 10.1111/j.1440-1746.2008.05319.x 1:CAS:528:DC%2BD1cXhtVOgu7jI (Pubitemid 352019379)
10. M Kainuma N Furusyo E Kajiwara K Takahashi H Nomura Y Tanabe, et al. 2010 Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C World J Gastroenterol 16 4400 4409 20845506 10.3748/wjg.v16.i35.4400 1:CAS:528:DC%2BC3cXhtF2rsLvJ
11. GR Foster MW Fried SJ Hadziyannis D Messinger K Freivogel O Weiland 2007 Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) and ribavirin Scand J Gastroenterol 42 247 255 17327945 10.1080/00365520600955526 1:CAS:528:DC%2BD2sXjtF2jsbY%3D
12. DM Jensen TR Morgan P Marcellin PJ Pockros KR Reddy SJ Hadziyannis, et al. 2006 Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 954 960 16628671 10.1002/hep.21159 1:CAS:528:DC%2BD28XkvFGmt7o%3D (Pubitemid 43724620)
13. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin, et al. 2004 Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 14996676 1:CAS:528:DC%2BD2cXitlOktrg%3D
14. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology. 2002; 36:S3-20.
15. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales, et al. 2002 Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 12324553 10.1056/NEJMoa020047 1:CAS:528: DC%2BD38Xnt12rtb0%3D
16. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindoller, et al. 2001 Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958 965 11583749 10.1016/S0140-6736(01)06102-5 1:CAS:528: DC%2BD3MXntF2qtb8%3D (Pubitemid 32913521)
17. P Halfon M Bourliere G Penaranda H Khiri D Ouzan, et al. 2006 Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection J Clin Microbiol 44 2507 2511 16825372 10.1128/JCM.00163-06 1:CAS:528:DC%2BD28Xot1aktLw%3D (Pubitemid 44092419)
18. MF Sabato ML Shiffman MR Langley DS Wilkinson A Ferreira-Gonzalez 2007 Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus J Clin Microbiol 45 2529 2536 17567786 10.1128/JCM.00058-07 1:CAS:528:DC%2BD2sXhtVehs7rK (Pubitemid 47295484)
19. M Schutten D Peters NKT Back M Beld K Beuselinck V Foulongne, et al. 2007 Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA J Clin Microbiol 45 1712 1717 17409216 10.1128/JCM.02385-06 1:CAS:528: DC%2BD2sXnsVKrt7c%3D (Pubitemid 46933896)
20. BDA Michelin Z Muller E Stelzl E Marth HH Kessler 2007 Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA J Clin Microbiol 38 96 100 1:CAS:528:DC%2BD2sXls1yguw%3D%3D (Pubitemid 46074454)
21. G Gerken T Rothaar MG Rumi R Soffredini M Trippler MJ Blunk, et al. 2000 Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination J Clin Microbiol 38 2210 2214 10834978 1:CAS:528: DC%2BD3cXksl2mt70%3D (Pubitemid 30414340)
22. EQ Konnick M Erali ER Ashwood DR Hillyard 2002 Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay J Clin Microbiol 40 768 773 11880391 10.1128/JCM.40.3.768-773.2002 1:CAS:528:DC%2BD38XisVKrsrw%3D (Pubitemid 34208621)
23. G Leckie G Schneider K Abravaya R Hoenle J Johanson J Lampinen, et al. 2004 Performance attributes of LCx HCV RNA quantitative assay J Virol Methods 115 207 215 14667537 10.1016/j.jviromet.2003.10.001 1:CAS:528: DC%2BD3sXps1Grs78%3D (Pubitemid 37506036)
24. SC Lee A Antony N Lee J Leibow JQ Yang S Soviero, et al. 2000 Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics J Clin Microbiol 38 4171 4179 11060086 1:CAS:528:DC%2BD3MXhs1Slurc%3D (Pubitemid 32233222)
25. J Hayashi M Ohmiya Y Kishihara Y Tani N Kinukawa H Ikematsu, et al. 1994 A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C Am J Gastroenterol 89 2151 2156 7977232 1:STN:280:DyaK2M%2FmslyhtQ%3D%3D (Pubitemid 24363660)
26. GL Davis JB Wong JG McHutchison MP Manns J Harvey J Albrecht 2003 Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 645 652 12939591 10.1053/jhep.2003.50364 1:CAS:528:DC%2BD3sXnvVKjt7s%3D (Pubitemid 37052151)
27. MT Pyne EQ Konnick A Phansalkar DR Hillyard 2009 Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay J Clin Microbiol 47 2872 2878 19625475 10.1128/JCM.02329-08 1:CAS:528:DC%2BD1MXht1Cqs7fI
28. K Matsuura Y Tanaka I Hasegawa T Ohno H Tokuda F Kurbanov, et al. 2009 Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients J Clin Microbiol 47 385 389 19091819 10.1128/JCM.01753-08 1:CAS:528:DC%2BD1MXjtVyltLc%3D
29. P Fytili C Tiemann C Wang S Schulz S Schaffer MP Manns, et al. 2007 Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay J Clin Virol 39 308 311 17625963 10.1016/j.jcv.2007.05.007 1:CAS:528: DC%2BD2sXnvF2lsbs%3D (Pubitemid 47079010)
30. RS Ross SO Viazov S Hoffmann M Roggendorf 2001 Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA J Clin Lab Anal 15 308 313 11793430 10.1002/jcla.1042 1:CAS:528:DC%2BD38XjvVSnsQ%3D%3D (Pubitemid 33097025)
31. M Gerotto F Dal Pero G Bortoletto A Ferrari R Pistis G Sebastiani, et al. 2006 Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse J Hepatol 44 83 87 16271794 10.1016/j.jhep.2005.08.016 1:CAS:528:DC%2BD2MXht12ktLjJ (Pubitemid 41772520)
32. JM Pawlotsky 2002 Molecular diagnosis of viral hepatitis Gastroenterology 122 1554 1568 12016423 10.1053/gast.2002.33428 1:CAS:528:DC%2BD38Xlt1CksLc%3D
33. JJ Feld JH Hoofnagle 2005 Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 967 972 16107837 10.1038/nature04082 1:CAS:528:DC%2BD2MXotFent7c%3D (Pubitemid 41191673)
34. T Suzuki 2010 A hepatitis C virus-host interaction involved in viral replicon: toward the identification of antiviral targets Jpn J Infect Dis 63 307 311 20858994
35. JM Pawlotsky H Dahari AU Neumann C Hezode G Germanidis I Lonjon, et al. 2004 Antiviral action of ribavirin in chronic hepatitis C Gastroenterology 126 703 714 14988824 10.1053/j.gastro.2003.12.002 1:CAS:528:DC%2BD2cXivFCisrc%3D (Pubitemid 38298318)
36. AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden, et al. 1998 Hepatitis C viral dynamics in vivo and the antiviral efficacy on interferon-alpha therapy Science 282 103 107 9756471 10.1126/science.282.5386. 103 1:CAS:528:DyaK1cXmsFOjsLc%3D (Pubitemid 28471138)
37. Sulkowski M, Vierling JM, Brown KA, Flamm SL, Kwo P, Mullen KD, et al. Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (PEG) plus ribavirin (RBV): results of the IDEAL trial. Hepatology. 2008;48:1144A (abstract).
38. Nyberg LM, Shiffman ML, Bonilla H, Hu KQ, Morgan TR, Levine RA, et al. Predicting the ability to achieve a sustained virologic response (SVR) in the first 12 weeks: results from the IDEAL study. Hepatology. 2008;48:1134A (abstract).